High Responses to Jaypirca in Relapsed CLL With BTK Mutations
December 20th 2023Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.
Read More
Arimidex/Faslodex And Enhertu Has Metastatic Breast Cancer Antitumor Activity
December 17th 2023Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.
Read More
Brukinsa Viabie for Calquence-Intolerant B-Cell Malignancies
December 12th 2023Results from an ongoing phase 2 study show the viability for the use of Brukinsa after patients with previously treated B-cell malignancies are deemed intolerant to the next-generation Bruton tyrosine kinase inhibitor Calquence.
Read More
Jakafi Results in Improved Control of Steroid Refractor/Dependent cGVHD
December 11th 2023The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.
Read More